Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study

Annals of Oncology

Volumn 15, Issue 4, 2004, Pages 638-645

  Schrijvers, D ^a   Van Herpen, C ^b   Kerger, J ^c   Joosens, E ^d   Van Laer, C ^a   Awada, A ^c   Van den Weyngaert, D ^d   Nguyen, H ^c   Le Bouder, C ^e   Castelijns, J A ^f   Kaanders, J ^b   De Mulder, P ^b   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JULES BORDET INSTITUTE   (Belgium)

^d MIDDELHEIM HOSPITAL   (Belgium)

^e SANOFI   (France)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 FU; Cisplatin; Combination chemotherapy; Docetaxel; Head and neck cancer; Phase I II

Indexed keywords

CIPROFLOXACIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; FEVER; HEAD AND NECK CANCER; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HUMAN; HYPOPHARYNX CARCINOMA; HYPOTENSION; INOPERABLE CANCER; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LARYNX CARCINOMA; LEUKOPENIA; LIVER TOXICITY; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OROPHARYNX CARCINOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; STOMATITIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 2342430140     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh145     Document Type: Article

References (28)

1. Adelstein DJ, Tan EH, Lavertu P. Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 1996; 24: 97-116.
2. Veteran Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
3. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899.
4. Kish J, Ensley J, Jacobs J et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 1985; 56: 2740-2744.
5. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272.
6. Forastiere AA. Head and neck cancer: Overview of recent developments and future directions. Semin Oncol 2000; 27 (Suppl 8): 1-4.
7. Schrijvers D, Vermorken JB. Update of the taxanes and other new agents in head and neck cancer. Curr Opin Oncol 1998; 10: 233-241.
8. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55: 5-30.
9. Braakhuis B, Kegel A, Welters M. The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 1994; 81: 151-154.
10. Huttmann C, Eckardt A, Pokas K et al. Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (Taxotere) in the nude mouse model. Mund Kiefer Gesichtschir 1999; 3: 257-262.
11. Bissery M, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 1995; 22 (Suppl 13): 3-16.
12. Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 533-537.
13. Dreyfuss A, Clark J, Norris C et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14: 1672-1678.
14. Couteau C, Chouaki N, Leyvraz S et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999; 81: 457-462.
15. Inuyama Y, Kataura A, Togawa K et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho 1999; 26: 107-116.
16. Glisson B, Murphy B, Frenette G et al. Phase II study of docetaxel and cisplatin combination in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1593-1599.
17. Baur M, Kienzer H, Schweiger J et al. First-line therapy in head and neck cancer with docetaxel and cisplatin. Ann Oncol 1998; 9 (Suppl 4): 75 (Abstr 362).
18. Mel J, Rodriguez R, Constenla M et al. Phase II study of docetaxel and cisplatin as induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Preliminary results. Proc Am Soc Clin Oncol 1999; 401a (Abstr 1549).
19. Schöffski P, Catimel G, Planting AS et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10: 119-122.
20. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000; 11: 845-849.
21. Caponigro F, Massa E, Manzione L et al. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2001; 12: 199-202.
22. Fillipi M, Cupissol D, Calais G et al. A phase II study of docetaxel and 5-fluorouracil in metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999; 402a (Abstr 1542).
23. Biakhov M, Shah P, Betka J et al. A randomized phase II Trial of taxotere (TXT) with Cisplatin (CDDP) or TXT with 5-Fluorouracil (5FU) in patients (PTS) with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2000; 19: 419a.
24. Van Den Neste E, de Valeriola D, Kerger J et al. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 2000; 6: 64-71.
25. Colevas AD, Busse PM, Norris CM et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16: 1331-1339.
26. Colevas A, Norris C, Tishler R et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17: 3503-3511.
27. Colevas AD, Norris CM, Tishler RB et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leuvorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002; 25: 153-159.
28. Posner M, Glisson B, Frenette G et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19: 1096-1104.